The Government has asked Baba Ramdev-led Patanjali Ayurved Ltd to stop advertising or promoting the ayurvedic drug Coronil, the allged drug to cure Covid-19 till it is scientifically verified.
The ministry of Ayurveda, Yoga & Naturopathy, Unani, Siddha and Homoeopathy (AYUSH) has ordered Patanjali to stop advertising the products—Coronil and Swasari and submit the details of the medicine and the trials, the company has reportedly carried. The Centre has warned the company to stop misleading advertising until the results are verified.
“Facts of the claim and details of the stated scientific study are not known to the Ministry… Patanjali Ayurved Ltd has been asked to provide at the earliest details of the name and composition of the medicines being claimed for COVID treatment; site(s)/hospital(s), where the research study was conducted for Covid-19; protocol, sample size, Institutional Ethics Committee clearance, Clinical Trials Registry- India registration and results data of the study (ies)…,” the ministry said in a statement on Tuesday.
From the order it seems that the company promoted by Baba Ramdev did not follow the protocols before rushing to launch the magic pill aimed at securing a pie from the huge corona-drug market especially when people are frantic to try anything and everything to stop the deadly virus.
The ministry asked Patanjali to submit details of the sample size, sites and hospitals where the research study was conducted and also for the Institutional Ethics Committee clearance.
“Patanjali Ayurved Ltd has been asked to provide at the earliest details of the name and composition of the medicines being claimed for COVID treatment; site(s)/hospital(s), where the research study was conducted for COVID-19; protocol, sample size, Institutional Ethics Committee clearance, CTRI registration and results data of the study (ies) and stop advertising/publicizing such claims till the issue is duly examined,” the ministry said in its statement.
While launching it, Ramdev had claimed that the first clinical controlled study was conducted on 280 patients in Delhi and Ahmedabad among many other cities.
